Amniotic Membrane Eye Side Effects and Complications

Amniotic membrane transplantation is one of the safer procedures in eye surgery, but it carries a defined set of side effects that range from temporary discomfort to, rarely, sight-threatening infection. The most common complaints are pain, foreign body sensation, and blurred vision while the membrane is in place, while more serious complications like microbial infection and graft displacement occur in a small minority of cases. Understanding which side effects are routine nuisances and which are warning signs makes a real difference in how quickly problems get addressed.

Pain, Foreign Body Sensation, and Blurred Vision

The side effects you are most likely to notice are the ones that start almost immediately. When an amniotic membrane is placed on or over the eye, it physically sits against the corneal surface, often held in place by a conformer ring or sutures. That means the eye registers something unfamiliar resting on it. In a case series of patients treated with the self-retained cryopreserved device ProKera, about 30% reported eye pain or headache.¹ A systematic review of sutureless amniotic membrane use found pain in roughly 3% of treated eyes, making it the single most frequently reported adverse effect in that dataset.²

Foreign body sensation and blurred vision are equally predictable. In patients with Sjögren syndrome treated with a cryopreserved amniotic membrane implant, these were the most common complaints.³ The blurriness is dramatic. When researchers tested a sutureless amniotic membrane patch on healthy volunteer eyes, distance vision dropped sharply within 30 minutes, and half of the eyes could not even read the largest line on a near-vision chart. Color vision, however, remained intact throughout.⁴ This is not a sign that something has gone wrong. The membrane itself is translucent tissue sitting directly on the cornea, and vision returns to baseline once it dissolves or is removed. Still, it means you should plan not to drive or perform visually demanding tasks while the membrane is in place.

Some patients also report a specific kind of discomfort from the conformer ring that holds the membrane in position. In a study treating neuropathic corneal pain, four eyes developed ring-related irritation, and another two had the implant disengage prematurely because of it. Even in those shortened-wear cases, pain scores still improved substantially.⁵ The ring discomfort tends to be worst in the first day or two and usually becomes more tolerable as the eye adjusts.

Membrane Displacement and Mechanical Failure

An amniotic membrane is fragile biological tissue, and keeping it where it needs to be is one of the practical challenges. The same systematic review that tracked pain rates found that displaced membranes or lost retaining rings occurred in just under 2% of eyes.² That sounds low in percentage terms, but for the patients it happens to, it means the membrane has stopped doing its job and may need to be replaced.

Displacement can happen more than once in the same patient. One case study documented a patient who needed three separate amniotic membrane applications because the membrane kept shifting off position, with displacements occurring at three and four days after placement.⁶ Even with repeat attempts, the overall per-patient success rate in that series was close to 78%, so persistence usually pays off. But each displacement resets the healing clock, which is frustrating when you are already dealing with a non-healing wound.

The risk of needing a repeat membrane is higher in eyes with more severe disease. In a retrospective study of eyes with infectious corneal ulcers, nearly half of the perforated eyes required a second membrane transplant, compared with about one in five non-perforated eyes.⁷ The lesson here is that the worse the starting condition of the eye, the harder it is for a single membrane to hold and do its work.

Infection After Amniotic Membrane Placement

Infection is the side effect that worries clinicians the most, even though it is uncommon. In a study of over 300 eyes that underwent amniotic membrane transplantation, culture-positive infections developed in about 3.4% overall. Gram-positive bacteria were the most frequently identified organisms, accounting for roughly two-thirds of the infections.⁸ That rate was not uniform across all patients. Eyes that already had active infection before the membrane was placed had a much higher infection rate (about 9%) compared with those that did not (under 2%), a statistically significant difference.

Fungal infections are rarer but can be particularly aggressive. Case reports have documented fungal keratitis appearing within days of membrane placement, including organisms not previously associated with amniotic membrane complications.⁹ These cases highlight that any new pain, redness, or worsening vision after membrane placement warrants an urgent check-in with your eye doctor, because fungal infections can be difficult to treat if caught late.

One source of infection risk comes from the membrane itself. Because amniotic membrane is donor tissue, there is an inherent possibility of transmitting bacterial, viral, or fungal organisms if the donor was not properly screened, or if the tissue was not processed and stored under strict sterile conditions.¹⁰ Modern tissue banks have detailed quality control protocols to minimize this, including rigorous donor screening and standardized preservation methods.¹¹ In practice, disease transmission from properly processed amniotic membrane is extraordinarily rare, but it is the reason your surgeon should be using tissue from a certified tissue bank rather than any unregulated source.

Inflammation, Granulomas, and Immune Reactions

Even though amniotic membrane is considered “immune-privileged” tissue, meaning it is less likely to trigger a rejection response than many other transplanted materials, it is not invisible to your immune system. A comparative study of pterygium surgery found that one month after the operation, signs of conjunctival inflammation were present in about 84% of eyes that received an amniotic membrane graft, versus only 15% of eyes that received a conjunctival autograft (tissue taken from the patient’s own eye). More than 60% of the amniotic membrane group needed a steroid injection to control the inflammation, compared with 10% in the autograft group.¹²

That study also noted that pyogenic granulomas, small fleshy growths that form in response to inflammation, developed in about 16% of the amniotic membrane group versus 5% in the autograft group. While the difference was not statistically significant given the small sample size, the pattern is consistent with the general finding that amniotic membrane provokes more short-term inflammation than a person’s own conjunctival tissue. These granulomas are typically treatable with topical steroids or minor excision, but they add recovery time and discomfort.

Frank graft rejection, where the body mounts a full immune attack on the membrane, is unusual. In a series of 65 eyes that underwent various types of amniotic membrane surgery, only two cases (about 3%) experienced outright rejection, both in eyes with active keratitis. Those eyes ultimately needed a full-thickness corneal transplant to prevent further damage.¹³ Chemosis, a puffing up of the membrane graft that looks alarming, was seen in one pterygium case in that same series but resolved with steroid drops.

Graft Retraction and Corneal Vascularization

Two other complications worth knowing about are graft retraction, where the membrane shrinks or pulls back from its intended coverage area, and corneal vascularization, where new blood vessels grow into the cornea. In the series mentioned above, graft retraction was mild and occurred in about 3% of cases, none severe enough to require repair. Corneal vascularization developed in about 5% of cases, mostly in eyes with prior chemical burns or chronic ulcers. The new vessels did not grow into the central visual area in any of those patients.¹³

These complications are generally more relevant in surgical (sutured) amniotic membrane transplants than in the self-retained devices used in office settings. The sutureless approach avoids the suture-related inflammation that can encourage blood vessel growth. A study of sutureless amniotic membrane patches for acute chemical eye burns found that vascularization rates were lower in the sutureless group compared with the sutured group.¹⁴ That study also found lower rates of symblepharon, a scarring condition where the eyelid fuses to the eyeball, in the sutureless group. Sutureless placement was simpler, faster, and associated with quicker healing, suggesting that when the clinical situation allows, avoiding sutures reduces the overall complication profile.

Recurrence of the Original Problem

A side effect that does not get enough attention is the recurrence of whatever condition the membrane was placed to treat. In a ProKera case series, 20% of eyes had recurrence of the primary pathology.¹ For pterygium surgery, recurrence was seen in about 5% of cases in another series, with higher recurrence in more advanced or previously recurrent pterygium.¹³ These are not failures of the membrane itself so much as reflections of the underlying disease’s tendency to return. But from your perspective as a patient, a recurrence is a complication of the treatment experience, even if the biology behind it would have reasserted itself regardless of the graft type.

Patients with Stevens-Johnson syndrome or toxic epidermal necrolysis face particularly high rates of ongoing problems after amniotic membrane treatment. In a long-term follow-up study of these patients, 40% of eyes needed a repeat membrane transplant. And even among eyes that healed initially, the most common chronic-phase complications were meibomian gland disease (affecting 78% of eyes) and persistent dry eye (58%).¹⁵ These outcomes reflect the severity of the underlying autoimmune damage rather than side effects of the membrane per se, but they set realistic expectations: amniotic membrane transplantation in severe disease is often the first step in a long journey, not a one-time fix.

Cryopreserved Versus Dehydrated Membranes

Not all amniotic membranes are the same product, and the processing method affects the side-effect profile. The two main types available are cryopreserved (frozen in a preservation medium) and dehydrated (dried). A comparative study found that patients who received cryopreserved membranes reported more side effects overall than those who received dehydrated membranes at both follow-up intervals. However, the cryopreserved group also reported greater vision improvement and a greater sense of wellness.¹⁶ Meanwhile, the dehydrated group was less likely to need repeat treatments and achieved a higher percentage of complete resolution of the underlying condition.

A separate comparison of cryopreserved and dehydrated sutureless membranes for persistent epithelial defects found that both were effective with comparable outcomes in terms of resolution and improvement, though specific adverse events differed between the two formats.¹⁷ The practical upshot is a tradeoff: cryopreserved membranes tend to have more bioactive growth factors and may offer stronger healing signals, but they cause more discomfort while they are on the eye. Dehydrated membranes are thinner, more comfortable, and dissolve more predictably, but may provide less biological activity. Your ophthalmologist will typically choose based on how severe your condition is and how much they need the membrane to do beyond simple coverage.

Effects on Corneal Clarity After Healing

A question patients sometimes raise is whether the membrane leaves any lasting mark on the cornea. Most of the time, amniotic membrane dissolves or integrates without leaving visually significant haze. However, one study of patients who had PRK laser eye surgery with an amniotic membrane graft placed afterward found an unexpected result: eyes that received the membrane actually showed increased corneal densitometry, meaning more light scatter through the cornea, rather than less. The membrane did not reduce haze as hoped.¹⁸ This finding is specific to the post-PRK context and does not necessarily apply to other uses, but it is a reminder that the assumed benefits of amniotic membrane do not always play out as expected in every clinical scenario.

Intraocular Pressure Considerations

Amniotic membrane is sometimes used in glaucoma surgery, specifically in bleb revision procedures aimed at maintaining healthy fluid drainage from the eye. One study comparing bleb revision with and without amniotic membrane found that while both approaches lowered intraocular pressure, the group that received the amniotic membrane ended up with higher average postoperative pressure than the group without it.¹⁹ The membrane group averaged a pressure of about 16 mmHg compared with about 12 mmHg in the non-membrane group, a statistically significant difference. This does not mean amniotic membrane worsens glaucoma outcomes in all contexts, but it suggests the membrane’s tissue-building properties may sometimes work against the goal of maintaining a thin, well-draining surgical bleb. If you have glaucoma and your surgeon is considering amniotic membrane as part of your procedure, this is worth discussing.

Children and Amniotic Membrane Safety

Pediatric use of amniotic membrane is less well-studied, which can make parents understandably nervous. A scoping review of clinical applications in children found that reported benefits included pain reduction, improved healing, antimicrobial effects, and reduced inflammation and vascularization. Reassuringly, no associated complications were reported in the pediatric studies reviewed.²⁰ That said, the absence of reported complications in a small body of literature is not the same as proof of safety. Pediatric eyes are still developing, and the studies are few. The existing evidence is encouraging but thin, which is worth keeping in mind if your child’s ophthalmologist recommends the procedure.

What Warrants an Urgent Call to Your Doctor

Most of the side effects described above, the blurriness, the foreign body sensation, mild pain, are expected parts of the experience and resolve on their own or with the membrane’s removal. But a few signs should prompt you to contact your ophthalmologist right away rather than waiting for your next scheduled visit:

Worsening pain: Pain that increases after the first couple of days, rather than gradually improving, can signal infection or an inflammatory reaction that needs treatment.
New discharge: Thick, colored, or increasing discharge may indicate a bacterial or fungal infection developing under or around the membrane.
Sudden vision drop: Beyond the expected blur from the membrane itself, a new or dramatic decrease in vision could mean the membrane has displaced, the underlying condition has worsened, or a complication like a corneal perforation needs attention.
Increasing redness: Some redness is normal post-procedure, but progressive redness or a red mass forming on the white of the eye could be a pyogenic granuloma or a sign of significant inflammation.

The challenge with amniotic membrane complications is that many of them mimic the symptoms of normal post-procedure recovery. Pain after eye surgery is expected. Blurriness with a membrane on your eye is expected. The distinguishing feature of a real problem is usually the trajectory: symptoms that are getting worse instead of gradually better, or new symptoms appearing after a period of stability. When in doubt, a quick phone call or visit is always a better gamble than waiting.

Tissue Banking and Quality Assurance

One underappreciated factor in your risk profile is where the membrane came from. Because amniotic membrane is human donor tissue, the quality of the tissue bank’s collection, screening, preservation, and storage processes directly affects how safe the product is when it reaches your eye. A well-run tissue bank with standardized protocols can distribute thousands of membrane patches over many years with reproducible safety results.²¹ In many countries, tissue banks operate under regulatory frameworks similar to those governing blood banks, with mandatory donor screening for communicable diseases and standardized processing conditions.

You are unlikely to have a choice of tissue bank as a patient, but you can ask your surgeon whether the membrane is sourced from a certified bank and what processing method was used. If the membrane is being applied in an office setting using a commercial device like ProKera or AmbioDisk, the product has been processed by an FDA-registered tissue establishment, which provides a baseline level of quality assurance. For sutured grafts used in the operating room, the tissue similarly comes through regulated channels in most healthcare systems. The rare case reports of disease transmission or contamination in the literature almost always trace back to lapses in processing standards, not to an inherent problem with the tissue itself.

1
Eye & Contact Lens. Evaluation of the Role of ProKera in the Management of Ocular Surface and Orbital Disorders
2
PubMed Central. The Efficacy of Sutureless Amnion Membrane Transplantation for Corneal Epithelialization in Delayed Corneal Healing: A Systematic Review
3
PubMed Central. The use of self-retained, cryopreserved amniotic membrane for the treatment of Sjögren syndrome: a case series
4
PubMed. Evaluation of visual acuity and color vision in normal human eyes with a sutureless temporary amniotic membrane patch
5
PubMed Central. Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain
6
PubMed Central. Clinical Outcomes of In-office Sutureless Amniotic Membrane Transplantation in Persistent Epithelial Defect
7
Taylor & Francis Online (Ocular Immunology and Inflammation). Effect of Amniotic Membrane Transplantation on Corneal Ulcers Due to Infectious Keratitis: A Retrospective Analysis
8
PubMed. Incidence of microbial infection after amniotic membrane transplantation
9
American Journal of Ophthalmology Case Reports. Fungal keratitis after amniotic membrane placement
10
PubMed Central. Human amniotic membrane transplantation: Different modalities of its use in ophthalmology
11
PubMed Central. Amniotic Membrane Transplantation in Ophthalmology: An Updated Perspective
12
PubMed. Postoperative conjunctival inflammation after pterygium surgery with amniotic membrane transplantation versus conjunctival autograft
13
PubMed Central. Amniotic membrane transplantation: An option for ocular surface disorders
14
Journal of Burn Care & Research. A Modified Symblepharon Ring for Sutureless Amniotic Membrane Patch to Treat Acute Ocular Surface Burns
15
PubMed Central. Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis
16
PubMed Central. Comparing tolerability and outcomes of cryopreserved and dehydrated amniotic membrane transplantations in the management of corneal disease
17
PubMed. Comparison of Persistent Epithelial Defect Treatment With Sutureless Cryopreserved and Dehydrated Amniotic Membrane
18
Journal of Refractive Surgery. Assessment of corneal haze after prk and the effect of sutureless amniotic membrane graft by corneal densitometry
19
PubMed Central. Efficacy of amniotic membrane-assisted bleb revision for elevated intraocular pressure after filtering surgery
20
PubMed Central. Clinical applications of the amniotic membrane in pediatric ocular pathology: a scoping review
21
PubMed Central. Amniotic membranes in ophthalmology: long term data on transplantation outcomes